Evidence map›Paper›PMID 32628931›Full record

ArticleThe American journal of pathology2020

Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms.

Kimon V Argyropoulos, Antonio Serrano, Jiyuan Hu, Margaret Black, Xiaojun Feng, Guomiao Shen, Melissa Call, Min J Kim, Andrew Lytle, Brendan Belovarac and 9 more

RetractedAbstract read
In one paragraph

Article in The American journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 106 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Potential role of PIM1 inhibition in the treatment of SARS-CoV-2 infection.Journal, genetic engineering & biotechnology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Retraction · 2020-07-07Date of Article and/or Notice Unknown · Duplication of Content through Error by Journal/Publisher · Removed ·
5 · Who and what money

Authors and funding

19 authors.

Kimon V ArgyropoulosDepartment of Pathology, NYU Langone Health, New York, New York.
Antonio SerranoDepartment of Pathology, NYU Langone Health, New York, New York.
Jiyuan HuDepartment of Population Health, NYU Grossman School of Medicine, New York, New York.
Margaret BlackDepartment of Pathology, NYU Langone Health, New York, New York.
Xiaojun FengDepartment of Pathology, NYU Langone Health, New York, New York.
Guomiao ShenDepartment of Pathology, NYU Langone Health, New York, New York.
Melissa CallInterdisciplinary Melanoma Program, New York University School of Medicine, New York, New York.
Min J KimInterdisciplinary Melanoma Program, New York University School of Medicine, New York, New York.
Andrew LytleDepartment of Pathology, NYU Langone Health, New York, New York.
Brendan BelovaracDepartment of Pathology, NYU Langone Health, New York, New York.
Theodore VougiouklakisDepartment of Pathology, NYU Langone Health, New York, New York.
Lawrence H LinDepartment of Pathology, NYU Langone Health, New York, New York.
Una MoranInterdisciplinary Melanoma Program, New York University School of Medicine, New York, New York; Center for Biospecimen Research and Development, NYU Langone Health, New York, New York.
Adriana HeguyDepartment of Pathology, NYU Langone Health, New York, New York.
Andrea TroxelDepartment of Population Health, NYU Grossman School of Medicine, New York, New York.
Matija SnuderlDepartment of Pathology, NYU Langone Health, New York, New York.
Iman OsmanInterdisciplinary Melanoma Program, New York University School of Medicine, New York, New York; Center for Biospecimen Research and Development, NYU Langone Health, New York, New York; Department of Dermatology, NYU Langone Health, New York, New York.
Paolo CotziaDepartment of Pathology, NYU Langone Health, New York, New York; Center for Biospecimen Research and Development, NYU Langone Health, New York, New York. Electronic address: paolo.cotzia@nyulangone.org.
George JourDepartment of Pathology, NYU Langone Health, New York, New York; Department of Dermatology, NYU Langone Health, New York, New York. Electronic address: george.jour@nyulangone.org.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
NCI NIH HHS P30 CA016087
6 · The paper itself

Abstract

The dynamics of viral load (VL) of the severe acute respiratory syndrome coronavirus 2 and its association with different clinical parameters remain poorly characterized in the US patient population. Herein, we investigate associations between VL and parameters, such as severity of symptoms, disposition (admission versus direct discharge), length of hospitalization, admission to the intensive care unit, length of oxygen support, and overall survival in 205 patients from a tertiary care center in New York City. VL was determined using quantitative PCR and log10 transformed for normalization. Associations were tested with univariate and multivariate regression models. Diagnostic VL was significantly lower in hospitalized patients than in patients not hospitalized (log10 VL = 3.3 versus 4.0; P = 0.018) after adjusting for age, sex, race, body mass index, and comorbidities. Higher VL was associated with shorter duration of the symptoms in all patients and hospitalized patients only and shorter hospital stay (coefficient = -2.02, -2.61, and -2.18; P < 0.001, P = 0.002, and P = 0.013, respectively). No significant association was noted between VL, admission to intensive care unit, length of oxygen support, and overall survival. Our findings suggest a higher shedding risk in less symptomatic patients, an important consideration for containment strategies. Furthermore, we identify a novel association between VL and history of cancer. Larger studies are warranted to validate our findings.

Indexed as

Viral LoadAdultBetacoronavirusCoronavirus InfectionsCOVID-19FemaleHospitalizationHumansMaleMiddle AgedNew York CityPandemicsPneumonia, ViralRisk FactorsSARS-CoV-2

Identifiers

PMID32628931
PMCPMC7332909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.